[The incidence of major histocompatibility system antigens in dilated and ischemic myocardiopathies].
OBJECTIVE
The purpose of this study was to analyze the frequency of the different antigens of HLA in patients with diagnosis of very advanced dilated cardiomyopathy and ischemic heart disease by comparing them with a control group of supposedly healthy subjects.


METHODS
The group of dilated cardiomyopathy consisted of 35 patients (8 women and 27 men) aged between 14 and 60 years. The group of ischemic heart disease included 32 patients (4 women and 28 men) aged between 34 and 64 years. The control group comprised 1337 subjects of the Spanish Mediterranean area, supposedly healthy and recruited from paternity studies.


RESULTS
In dilated cardiomyopathy we found a higher incidence in comparison with the control group of the A-2 (62.86% vs 46.22%), B-12 (60.00% vs 32.38%) and DQ-3 (82.86 vs 49.96%) antigens, and a lower incidence of B-51 (0.00% vs 12.49%). In ischemic heart disease we found, when comparing to the control group, a higher incidence of A-11 (31.25% vs 13.08%) and A-29 (34.38% vs 14.58%) antigens and a lower incidence of DQ-2 (15.63% vs 49.88%).


CONCLUSIONS
In the Spanish Mediterranean area, the presence of A-2, B-12 and DQ-3 antigens, as well as the absence of B-51 would favour the appearance of advanced dilated cardiomyopathy. The presence of the A-11 and A-29 antigens would predispose to ischemic cardiomyopathy while the presence of DQ-2 would have a protective effect on the appearance of this cardiopathy.
D000293:Adolescent; D000328:Adult; D002311:Cardiomyopathy, Dilated / Q000453:epidemiology / Q000276:immunology*; D016009:Chi-Square Distribution; D005260:Female; D006680:HLA Antigens / Q000097:blood*; D006801:Humans; D015994:Incidence; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000276:immunology*; D016036:Seroepidemiologic Studies; D013030:Spain / Q000453:epidemiology
D006680:HLA Antigens
Incidencia de los antígenos del sistema mayor de histocompatibilidad en la miocardiopatía dilatada e isquémica.